In the present study, we developed a recombinant immunotoxin using the C5 sdAb, a promising rabbit-derived sdAb antibody targeting canine B-cell lymphoma, previously developed by our group. This evidence concerns the gene C5 and B-cell non-Hodgkin lymphoma.